CMS released the Medicare Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System on November 2, 2018. This blog provides an overview of the key takeaways, including a distilled list with four implications of the changes and the ramifications for your ASC.
Comments made by CMS Administrator Seema Verma earlier this year have raised speculation that a major overhaul of the Stark law could be in the works, and the announced changes could have implications for health systems developing risk-based and value-focused models.
Amazon’s newest breakthrough involves Alexa (Amazon’s voice assistant) becoming HIPAA compliant. Such a shift may result in a more immediate impact for patients, because Alexa will now be able to directly manage people’s health information.
Hospitals and health systems are gearing up for a new rule book that could have major ramifications for their cardiovascular service line and structural heart program.
As healthcare continues to shift from a volume to value orientation, observers across the country are increasingly raising concerns over how the Stark law and Anti-Kickback Statute (AKS) limit the ability of providers to participate in and be appropriately compensated for care coordination.
The first performance period for the CMS Bundled Payments for Care Improvement Advanced (BPCI-A) program began on October 1, 2018. Now with the program having started, if you are a BPCI-A participant, you may be wondering how you can operationalize your bundled payment initiatives to position your organization for success.
In a ruling called “Pathways to Success,” the Centers for Medicare & Medicaid Services has overhauled the Medicare Shared Savings Program (MSSP), accelerating the path to financial risk for MSSP ACOs.
As we look forward to 2019, the hospital/health system M&A market is increasingly becoming a bifurcated landscape of clear “haves” and “have-nots”.
On December 27, 2018, the United States District Court for the District of Columbia granted a permanent injunction on the 2018 Medicare reimbursement cuts related to 340B drugs. What does this mean for the hospitals affected by these changes?
Page 1 of 9